Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.57 |
| ▸ | MAPK10 | P53779 | 5/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26965221 | 1.00 | MAPK14 (0.57) | MAPK14MAPK10MAPK13MAPK12MAPK11 | |
| SCHEMBL26965273 | 0.87 | MAPK14 (0.54) | MAPK14MAPK10MAPK13MAPK12MAPK11 | |
| SCHEMBL26965257 | 0.86 | MAPK14 (0.57) | MAPK14MAPK10MAPK13MAPK12MAPK11 | |
| SCHEMBL29429988 | 0.86 | MAPK14 (0.57) | MAPK14MAPK10MAPK13MAPK12MAPK11 | |
| SCHEMBL26965125 | 0.84 | MAPK14 (0.56) | MAPK14MAPK10 | |
| SCHEMBL29429909 | 0.83 | MAPK14 (0.46) | MAPK14MAPK10MAPK13MAPK12MAPK11 | |
| SCHEMBL26965202 | 0.81 | MAPK14 (0.54) | MAPK14MAPK10MAPK13MAPK12MAPK11 | |
| SCHEMBL26965249 | 0.80 | EGFR (0.61) | MAPK14MAPK10EGFR | |
| SCHEMBL29429950 | 0.80 | EGFR (0.61) | MAPK14MAPK10EGFR | |
| SCHEMBL26965252 | 0.79 | MAPK14 (0.37) | MAPK14MAPK10MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022067063-A1 | MUTANT SELECTIVE EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-03-31 | — | — | WO | disclosed |